Fibromuscular dysplasia (FMD) encompasses a heterogeneous
|
|
- Jessica Bridges
- 5 years ago
- Views:
Transcription
1 Efficacy of Revascularization For Renal Artery Stenosis Caused by Fibromuscular Dysplasia A Systematic Review and Meta-Analysis Ludovic Trinquart, Claire Mounier-Vehier, Marc Sapoval, Nathalie Gagnon, Pierre-François Plouin Abstract In patients with fibromuscular dysplasia and renal artery stenosis, renal artery revascularization has been used to cure hypertension or to improve blood pressure control. To provide an up-to-date assessment of the benefits and risks associated with revascularization in this condition, we performed a systematic review of studies in which hypertensive patients with fibromuscular dysplasia renal artery stenosis underwent percutaneous transluminal renal angioplasty or surgical reconstruction. We assessed how often periprocedural complications and hypertension cure and improvement occurred. We selected 47 angioplasty studies (1616 patients) and 23 surgery studies (14 patients). Combined rates of hypertension cure, defined according to the criteria in each study, after angioplasty or surgery were estimated to be 46% (95% CI: 4% to 52%) and 58% (95% CI: 53% to 62%), respectively, with substantial variations across studies. The probability of being cured was negatively associated with patient age and time of publication. Cure rates using current definitions of hypertension cure (blood pressure 14/9 mm Hg without treatment) were only 36% and 54% after angioplasty and surgery, respectively. The combined risks of periprocedural complications were 12% and 17% after angioplasty and surgery, respectively, with less major complications after angioplasty than surgery (6% versus 15%). In conclusion, angioplasty or surgical revascularization yielded moderate benefits in patients with fibromuscular dysplasia renal artery stenosis, with substantial variation across studies. The blood pressure outcome was strongly influenced by patient age. (Hypertension. ;56: ) Key Words: renal artery stenosis fibromuscular dysplasia revascularization percutaneous transluminal angioplasty surgical reconstruction systematic review meta-analysis Fibromuscular dysplasia (FMD) encompasses a heterogeneous group of idiopathic, segmental, nonatherosclerotic diseases of the musculature of arterial walls, leading to the narrowing of small and medium-sized arteries. 1 FMD is the second most frequent cause of renal artery stenosis (RAS) after atherosclerosis. Renal artery revascularization through surgical reconstruction and percutaneous renal transluminal angioplasty (PTRA) has been used to treat hypertensive patients with RAS and presumed renovascular hypertension. Atherosclerotic RAS mostly affects elderly patients with frequent renal parenchymal disease. 2 Conversely, FMD predominantly affects women in their 3s or 4s with normal kidney function. Because advanced age and chronic kidney disease are associated with a poor outcome after etiologic treatment, 2,3 blood pressure (BP) outcome after renal artery revascularization is expected to be more favorable in patients with FMD than in patients with atherosclerosis. An overview, published within years of PTRA being first used, reported a mean rate of hypertension cure after PTRA (defined according to each study criteria) of 5% in 193 patients with FMD RAS versus 19% in 464 patients with atherosclerotic RAS. 4 Over the last years, several randomized, controlled trials and systematic reviews have assessed the efficacy of surgical reconstruction or PTRA for atherosclerotic RAS and confirmed the limited benefit of revascularization in this condition. 5 9 By contrast, there have been no randomized, controlled trials and no comprehensive systematic reviews assessing the BP outcome associated with revascularizing FMD stenoses. Our primary objective was to systematically review and assess the rate of hypertension cure after renal artery revascularization (using surgery or PTRA) in patients with hypertension and fibromuscular RAS. Secondary objectives were to assess the technical success rates of revascularization and Received March 5, ; first decision March 27, ; revision accepted June 21,. From the Institut National de la Santé et de la Recherche Médicale Centre d Investigation Clinique et Epidémiologie Clinique 4 (L.T.), Paris, France; Université Lille 2 (C.M.-V.), Faculté demédecine Henri Warembourg, Centre Hospitalier Universitaire et Régional de Tours, Hôpital Cardiologique, Service de Médecine Vasculaire et Hypertension, Lille, France; Université Paris Descartes (M.S.), Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Radiologie Cardiovasculaire, Paris, France; Université Paris Descartes (N.G., P.-F.P.), Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Médecine Vasculaire et Hypertension, Institut National de la Santé etde la Recherche Médicale U 97, Paris, France. Correspondence to Pierre-François Plouin, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, rue Leblanc, 7598 Paris Cedex 15, France. pierre-francois.plouin@egp.aphp.fr American Heart Association, Inc. Hypertension is available at DOI:.1161/HYPERTENSIONAHA
2 526 Hypertension September the risk of complications. Our third objective was to explore variation in outcomes across subgroups. Methods Selection Criteria and Search Method for Identifying Studies Studies were considered eligible if: (1) they enrolled hypertensive patients with fibromuscular RAS; (2) patients underwent renal artery revascularization by surgical reconstruction or PTRA; and (3) the number of patients with hypertension cure could be identified. We searched Medline and Embase for all of the studies published before and including October 9. Complete search strategies are available in the online Data Supplement (please see Table S1). We screened the reference lists of primary articles and relevant reviews. We also screened textbooks on vascular medicine and interventional radiology, as well as conference proceedings from the Society of Interventional Radiology and proceedings from the Cardiovascular and Interventional Radiological Society of Europe annual meetings ( 8). Studies in languages other than English were not. Case reports and studies concerning 5 patients were. 781 records on the basis of title 143 records on the basis of abstract 91 records on the basis of full-text article 86 records identified through Medline and Embase database searching 35 abstracts screened 162 full-text articles assessed for eligibility 98 eligible articles 42 records identified through hand searching (reference lists, textbooks, conference proceedings) 15 records on the basis of full-text article Selection of Studies and Data Collection Two authors independently applied the selection criteria to all of the reports identified by the search strategy. Final selection was based on a review of full-text articles. Any disagreement regarding selection was discussed to obtain consensus. Only the most recent article was analyzed for multiple publications of a given study or when we could not exclude the possibility of overlapping populations. Two authors extracted data concerning baseline patient characteristics (age, sex, BP, and known duration of hypertension), FMD characteristics (criteria for FMD diagnosis, unilateral or bilateral disease, and medial or nonmedial FMD type), and revascularization techniques. Criteria for FMD diagnosis were present if renal angiography, the appearance of FMD lesions after angiography (medial-type FMD with multiple stenoses and the string-of-beads appearance or focal of tubular type FMD lesions), or histological confirmation was reported. Studies were judged to be at lower risk of bias in cases of prospective recruitment, consecutive recruitment, adequate description of the study population (at least mean age, mean baseline BP, and clinical criteria for revascularization), complete follow-up (hypertension cure assessed in % of patients with a successful procedure), and adequate outcome measurement (hypertension cure defined and assessed 1 days after revascularization for all of the patients). Outcome and Data Analysis The primary outcome was the rate of hypertension cure defined according to each study. Secondary outcomes included the technical success rate, the rate of periprocedural complications, the rate of hypertension cure or improvement (improvement being defined according to each study), and the effect of revascularization on renal function. Complications were classified according to localization (renal, puncture site, or cardiovascular complications) and severity (major or minor complications).,11 Renal complications included renal failure, embolization or infarction, and renal artery dissection, occlusion, thrombosis, perforation, or rupture. Puncture site complications included local hematoma or infection. Cardiovascular complications included nonrenal embolization or dissection. Major complications were those resulting in an additional procedure, unplanned treatment, prolonged hospitalization, transfusion, or death. For the meta-analysis, proportions were transformed into quantities via the Freeman-Tukey arcsine transformation. We computed a weighted mean of the individual transformed proportions using DerSimonian-Laird weights for the random effects model; the combined proportion was calculated through back transformation of the weighted mean. Inconsistencies in results across studies were assessed using the Cochran homogeneity 2 test and I 2 statistic. 19 because of possible overlapping populations 69 studies concerning PTA 5 studies concerning PTA 4 studies concerning surgery 25 studies concerning surgery 15 because of possible overlapping populations Figure 1. Flow diagram mapping out the numbers of records identified and included. To analyze variations in BP outcome, we first performed indirect comparisons between reports grouped according to the definition of hypertension cure. We then performed a sensitivity analysis to assess the small study effect on outcome rates. Because small-sized studies are prone to overestimating or underestimating BP outcome, we separated trials according to the median number of patients per study. We then performed subgroup analyses comparing patients with bilateral and unilateral RAS, those with medial and nonmedial FMD, and those with branch and nonbranch stenosis. Lastly, we performed meta-regression analyses to assess the influence of mean age, known duration of hypertension, baseline BP, and duration of follow-up on the outcome. Meta-regression models were used to assess the potential changes in rates of technical success, complications, and hypertension cure with time assessed based on the publication year. The meta-regression model was a logistic-normal model with binomial data and random effects. Results Selection of Studies Of the 86 records identified from our electronic search, 71 articles were deemed eligible. We identified an additional 27 eligible articles through manual searches. These 98 articles reported results from 69 series of patients treated with PTRA and from 4 series of patients treated with surgery. Among these, we 19 PTRA and 15 surgery studies over possible overlapping populations (please see Table S2). Finally, 5 studies concerning PTRA and 25 studies concerning surgery were included (Figure 1). Of these, 3 PTRA and 2 surgery studies specifically concerned pediatric populations
3 Trinquart et al Revascularization of FMD Renal Artery Stenosis 527 Table 1. Patient Characteristics in FMD Patients Treated by PTRA or Surgery PTRA Surgery Available Data Grand Mean Available Data Grand Mean No. of No. of (Range of Means No. of No. of (Range of Means Variable Studies Patients Across Studies) Studies Patients Across Studies) Age, y (28 to 59) (24 to 45) Men % ( to 5) % ( to 43) Bilateral RAS % ( to 67) % (6 to 48) Systolic/diastolic BP, mm Hg (145 to 192)/8 (89 to 143) (157 to 7)/112 (1 to 128) No. of antihypertensive drugs (1.2 to 3.3) (1.7 to 2.2) Known duration of hypertension, y (2.5 to 13) (3.3 to.) Medial FMD % (26 to 85) % (57 to 82) (please see Tables S3 and S4 for the list of references to selected studies and reasons for excluding full-text articles). Results of PTRA Study Characteristics Among the 47 studies relating to PTRA, 3 were prospective, 14 reported consecutive patients, 18 provided the minimum required information on the study population, and 38 reported a complete follow-up of patients. Hypertension cure was defined in 41 studies and was assessed 1 days after revascularization in 22 studies. In the 47 series consisting of 1616 patients with RAS caused by FMD and treated with PTRA, the median number of patients per series was (range: 5 to 442). Patient Characteristics FMD diagnosis criteria were reported in only 23 studies. Baseline characteristics were not reported exhaustively. Where reported, the mean age was 42 years, the proportion of men was 19%, the proportion of patients with bilateral RAS was 26%, and the proportion with medial FMD was 67% (Table 1). The minimal stenosis grade leading to PTRA was reported in 14 series: it was 25% in 1, 5% in 5 (and/or a 15% peak systolic pressure gradient in 1 series), 6% in 3, 7% in 2, 75% in 2, and was 8% in 1 study. We found no mention of poststenotic dilatation or renin analysis to define high-grade stenosis. Detailed characteristics of individual studies are available in the online Data Supplement (please see Table S5). Procedure Outcome The description of procedures was frequently missing. 5-F sheaths were used in 3 series, 6-F sheaths in 1 series, and both 5-F and 7-F sheaths were used in another series. Seven studies involved.35-in guide wires, and the procedure was performed through the femoral puncture site for all of the patients in 4 studies, for 99% of patients in 1 study (humeral route in 1 patient), and 8% of patients in another study (axillary artery access in % of patients). Stents were used in 3 studies and involved a total of 8 patients. Technical success rates were reported in 27 studies (838 patients; 997 procedures). The combined success rate was 88.2% [95% CI: 83.5 to 92.2], with considerable heterogeneity (range: 69.2% to.%; homogeneity test P.1; I 2 77% [95% CI: 67% to 84%]; see Figure S1). The meta-regression analysis showed no significant effects of time on the rate of technical success: the odds ratio (OR) associated with a publication date years later was 1.37 (95% CI:.74 to 2.54; P.32). Complications Complications were reported in studies (663 patients). The combined complication rate was 11.8% [95% CI: 8.2% to 15.9%] with substantial heterogeneity (range:.% to 42.9%; homogeneity test P.16; I 2 55% [95% CI: 16% to 72%]; Figure 2). The major and minor complication rates were 6.3% [95% CI: 4.1% to 9.%] and 5.3% [95% CI: 2.7% to 8.7%], respectively. The risk of mortality was.9% [95% CI:.3% to 1.7%]. The rates of puncture site and kidney complications were 3.4% [95% CI: 2.% to 5.1%] and 8.3% [95% CI: 5.% to 12.4%], respectively. Detailed forest plots for each complication are presented in the online Data Supplement (see Figure S2). The meta-regression analysis showed a nonsignificant trend toward an increased risk of complications with time (OR associated with a publication date years later: 1.63 [95% CI:.93 to 2.83]; P.). BP Outcome Hypertension cure rates were reported in the 47 series (1426 patients with follow-up). Follow-up durations showed large Complications (%) % (8.2 to 15.9) 3.4% (2. to 5.1) 8.3% (5. to 12.4) 1.2% (.5 to 2.3).9% (.3 to 1.7) 6.3% 5.3% (4.1 to 9.) (2.7 to 8.7) Puncture All Renal CV Death Major Minor Site Studies (663 patients) Figure 2. Meta-analysis of periprocedural complication rates after PTRA.
4 528 Hypertension September 8 All Studies Studies with or more patients Hypertension Cures (%) % (39.8 to 51.7) 35.8% (25.5 to 46.8) 49.% (4.6 to 57.6) 4% (31 to 48) 26.7% (17. to 37.7) 41% (3 to 52) Figure 3. Meta-analysis of hypertension cure rates after PTRA. 47 studies 1426 patients I 2 =77% (67 to 84) 11 studies 282 patients I 2 =69% (42 to 83) 24 studies 552 patients I 2 =74% (62 to 83) 22 studies 1142 patients I 2 =87% (82 to 91) 5 studies 5 patients I 2 =6% ( to 85) 11 studies 419 patients I 2 =81% (67 to 89) Definition of cure Any BP <14/9 mmhg without Rx DBP <9 mmhg without Rx Any BP <14/9 mmhg without Rx DBP <9 mmhg without Rx intrastudy and interstudy variation (mean follow-up was from 1 to 99 months). The definition for cure varied between studies: it was defined as BP levels 14/9 mm Hg without antihypertensive treatment in 11 studies; diastolic BP 9 mm Hg without treatment in 24 studies; diastolic BP 9 mm Hg (respectively, mm Hg) without treatment when patient age was 4 years (respectively, 4 years) in 1 study; a -mm Hg decrease in diastolic BP to a level 9 mm Hg in 2 studies; normotension without treatment in 5 studies; BP 15/9 mm Hg without treatment in 2 studies; and BP 16/95 mm Hg without treatment in 1 study. The definition was not clear in 1 study. Overall, the combined cure rate was 45.7% [95% CI: 39.8% to 51.7%], with considerable heterogeneity (range: 14% to %; homogeneity test P.1; I 2 78% [95% CI: 71% to 83%]; Figure 3). The definition of hypertension improvement also varied considerably across studies. The combined rate for cure or improvement was 86.4 [95% CI: 83.2 to 89.3], with substantial heterogeneity (range: 56% to %; homogeneity test P.1; I 2 58% [95% CI: 39% to 69%]). Detailed forest plots for each outcome are reported in the online Data Supplement (please see Figures S3 and S4). The rate of cure varied according to the definition of cure. It was 35.8% [95% CI: 25.5% to 46.8%] in the 11 studies using BP 14/9 mm Hg without treatment compared with 49.% [95% CI: 4.6% to 57.6%] in the 24 studies using diastolic BP 9 mm Hg without treatment (P.7). The sensitivity analysis restricted to the 22 studies with patients showed lower combined rates than the combined rates estimated for all 47 of the studies (Figure 3). In particular, the combined cure rate was 26.7% [95% CI: 17.% to 37.7%] in the 5 studies in which BP 14/9 mm Hg without treatment was used to define hypertension cure. Subgroup Analyses Combining the subgroup results from 6 trials (166 patients) showed no statistically significant difference in the cure rate between patients with bilateral and those with unilateral disease (combined risk ratio:.79 [95% CI:.36 to 1.77]; P.57), with substantial heterogeneity (homogeneity test P.3; I 2 6% [95% CI: % to 82%]; please see Figure S5). Combining the results from 2 trials (77 patients) showed a lower probability of cure in cases of medial FMD than in nonmedial FMD (combined risk ratio:.6 [95% CI:.39 to.93]; P.2), with moderate heterogeneity (homogeneity test P.32; I 2 not applicable; please see Figure S6). Combining the results from 2 trials (129 patients) showed no statistically significant difference in the cure rate between patients with branch stenosis and those with other location stenoses (combined risk ratio:.89 [95% CI:.38 to 2.6]; P.78), without heterogeneity (homogeneity test P.83; I 2 not applicable; please see Figure S7). Finally, combining the results from 2 trials (89 patients) showed that the mean age was significantly lower among cured patients (combined standardized mean difference of.99 [95% CI: 1.54 to.43]; corresponding with a difference in mean age of years; P.5) without heterogeneity (homogeneity test P.98; I 2 not applicable). Similarly, the mean known duration of hypertension in these 2 studies tended to be lower among cured patients (combined standardized mean difference of.48 [95% CI: 1.2 to.6]; P.8) and without heterogeneity (homogeneity test P.63; I 2 not applicable). Meta-Regression Analyses Meta-regression analyses are reported in Table 2 and Figure 4. The probability of cure significantly decreased with increasing mean age (OR associated with an increase in mean age of years:.48 [95% CI:.39 to.59]) and mean known duration of hypertension (OR associated with an increase in mean hypertension duration of 5 years:.39 [95% CI:.23 to.67]). Finally, the probability of cure significantly decreased with time, as evaluated via the publication
5 Trinquart et al Revascularization of FMD Renal Artery Stenosis 529 Table 2. Univariate Meta-Regression Analyses Assessing the Relationship Between Hypertension Cure Rate and Patient or Study Characteristics in Series of FMD Patients Treated by PTRA or Surgery Variable Increase of Odds Ratio (95% CI) P PTRA Mean age, y.48 (.39 to.59).1 Mean systolic BP, mm Hg (.35 to 1.59).46 Mean diastolic BP, mm Hg (.95 to 3.47).9 Mean No. of antihypertensive drugs 1.57 (.24 to 1.39).24 Mean duration of hypertension, y 5.39 (.23 to.67).5 Mean follow-up, mo 6 1. (.99 to 1.1).97 Publication year.62 (.45 to.85).4 Surgery Mean age, y.84 (.58 to 1.23).39 Mean follow-up, mo 6.97 (.91 to 1.3).36 Publication year.81 (.62 to 1.7).15 year (OR associated with an increase of years:.62 [95% CI:.45 to.85]). Repeat PTRA Repeated PTRA between initial revascularization and hypertension cure was reported in series (357 patients who underwent follow-up). In these series, the combined proportion of patients receiving a secondary procedure was estimated to be 18.2% [95% CI: 11.% to 26.8%], with considerable heterogeneity (range: 8% to 56%; homogeneity test P.1; I 2 68% [95% CI: 23% to 82%]). Renal Outcome The effect of revascularization on renal function was assessed in 7 studies (7 patients) and showed no differences between mean creatinine levels at baseline and at follow-up (please see Table S6). Pediatric Cases Three series specifically involved pediatric populations with FMD treated using PTRA (47 patients with a mean age of 9 years, of which 49% were men). In 1 study, hypertension cure was defined by a BP lower than that of the 95th percentile for age and sex without treatment and assessed at a minimum of 6 months after PTRA; all 3 children (%) were completely cured of hypertension, with no complications, and remained hypertension free for 2 years after PTRA. In the other 2 series, hypertension cure was defined as normotensive without treatment and was assessed after a mean follow-up of 14 months (range: 1 to 6 months) and 87 months (range: 3 to 129 months), respectively. The hypertension cure rates were 67% (8 of 12 children) and 8% (4 of 5), respectively. Results of Surgery Study Characteristics Among the 23 series, there were 2 prospective studies, 3 with consecutive patients, 3 with the minimum required information on the study population, with a complete follow-up, in which hypertension cure was defined, and 15 in which Probability of hypertension cure (%) Probability of hypertension cure (%) Mean age (years) Publication year hypertension cure was measured 1 days after revascularization. In the 23 series consisting of 14 patients with RAS caused by FMD and treated using surgery, the median number of patients per series was 33 (range: 6 to 179). Several techniques were used in each series, the most frequent being aortorenal bypass graft using a saphenous vein or a prosthesis. Aortic reimplantation, resect anastomosis, and autotransplantation were also used. Eleven series included patients treated by primary nephrectomy. Separate analyses of BP outcome for each technique were not possible. Patient Characteristics FMD diagnosis criteria were reported in 14 studies. Where provided, the mean age was 36 years, and the proportion of men was %. The proportion of patients with bilateral RAS was 23%, and the proportion of patients with medial FMD was 7% (Table 1). Detailed characteristics of individual studies are available in the online Data Supplement (please see Table S7). Complications Mortality data were reported in 18 studies (778 patients), of which 16 series reported no death, yielding a combined Figure 4. Meta-regression analyses assessing the relationship between the hypertension cure rate after PTRA and mean age, publication year
6 53 Hypertension September perioperative risk of death estimated to be 1.2% [95% CI:.5% to 2.1%]. Complication rates were reported in 5 studies (222 patients). The combined complication rate was 16.9% [95% CI:.3% to 24.7%], with substantial heterogeneity (range: 5% to 28%; homogeneity test P.8; I 2 52% [95% CI: % to 81%]). The majority of reported complications were classified as major complications, and the major complication rate was estimated to be 15.4% [95% CI: 9.2% to 22.8%]. Detailed forest plots for each complication can be found in the online Data Supplement (see Figure S8). BP Outcome Assessing revascularization success by follow-up angiography was not mentioned. The hypertension cure rate was reported in the 23 selected series (5 patients with followup). Follow-up durations showed large variation: 4 series reported the immediate postoperative outcome, and in the other series, the mean follow-up ranged from 8 to months. The definition of cure varied across studies: it was defined as BP 14/9 mm Hg without treatment in 5 studies; diastolic BP 9 mm Hg without treatment in 12 studies; a -mm Hg decrease in diastolic BP to a level 9 mm Hg in 1 study; normotension without treatment in 2 studies; BP 15/9 mm Hg without treatment in 1 study; and diastolic BP mm Hg without treatment in 1 study. The definition was not clear in 1 study. Overall, the combined cure rate was 57.5% [95% CI: 53.% to 62.%], with substantial heterogeneity (range: 14% to %; homogeneity test P.1; I 2 47% [95% CI: 13% to 67%]). The definition of hypertension improvement also varied considerably across studies. The combined rate of cure or improvement was 88.3% [95% CI: 83.2% to 92.6%], with considerable heterogeneity (range: 62% to %; homogeneity test P.1; I 2 8% [95% CI: 7% to 86%]). Detailed forest plots for each outcome are reported in the online Data Supplement (please see Figures S9 through S11). The rate of hypertension cure tended to be lower in the 5 series (29 patients) that used BP 14/9 mm Hg without treatment than in the 12 series (442 patients) that defined cure as diastolic BP 9 mm Hg without treatment: 54.1% (95% CI: 44.1% to 64.%) versus 59.8% (95% CI: 52.8% to 66.7%; P.35). The sensitivity analysis restricted to the 12 studies with 33 patients (824 patients) showed a similar combined cure rate to that estimated using all 23 studies: 56.6% (95% CI: 5.3% to 62.8%). Moreover, the sensitivity analysis restricted to the studies without patients treated by nephrectomy (47 patients) also showed a similar combined rate (57.5% [95% CI: 51.1% to 63.7%]). Subgroup analyses were reported in a single series, which found no differences in cure rates between patients with bilateral and unilateral disease (15 of 27 versus 16 of 29; risk ratio: 1. [95% CI:.63 to 1.61]; P 1.) or cure rates between patients with medial and nonmedial lesions (18 of 32 versus 13 of 24; risk ratio: 1.4 [95% CI:.64 to 1.68]; P 1.). Meta-Regression Analysis Meta-regression analyses showed that the probability of hypertension cure tended to decrease with increasing mean age (OR associated with an increase in mean age of years:.84 [95% CI:.58 to 1.23]) and time, as evaluated via the publication year (OR associated with an increase of years:.81 [95% CI:.62 to 1.7]), but that these changes were not statistically significant (Table 2). Pediatric Cases Two series specifically concerned pediatric populations (6 patients; mean age: 12 years; men: 53%). Most children underwent aortorenal bypasses using saphenous vein (62%), whereas some underwent a nephrectomy (22%). Two retroperitoneal hematomas and a fatal thrombosis were reported in 1 study involving 27 children, and no complications were reported in the other. In 1 study, hypertension cure was defined as BP 15/9 mm Hg without treatment after a minimum follow-up of 6 months; in the other, it was defined as BP 14/9 mm Hg without treatment after a minimum follow-up of 12 months. Hypertension cure rates were 59.2% (16 of 27 children) and 87.9% (29 of 33), respectively. Discussion This systematic review identified 7 series of patients with RAS caused by FMD who underwent revascularization using PTRA or surgery (47 and 23 series totaling 1616 and 14 patients, respectively) and in whom postintervention follow-up allowed the assessment of BP outcome and, in most series, how often complications occurred. Most patients were women in their 4s. One patient in 4 had bilateral FMD. Hypertension cure after PTRA or surgery was obtained in 46% and 55% of patients, respectively, with large variations in cure rates across studies. The probability of cure was negatively associated with age, known duration of hypertension, medial-type FMD, time of publication, and more stringent definitions of cure. Cure rates based on current definition (BP 14/9 mm Hg without treatment) were only 36% and 54%, respectively, after PTRA and surgery. The risk of periprocedural complications was substantial, estimated at 12% after PTRA and 17% after surgery. However, major complications tended to be less frequent after PTRA than after surgery (6% versus 15%), but selection criteria may have differed between study populations. The risk of death was estimated to be.9% after PTRA and 1.2% after surgery. The earlier review of PTRA published by Ramsay and Waller ( series, 193 patients with FMD RAS) 4 reported rates of cure of 5%. A more recent review by Matsumoto et al (26 series, 552 patients) 12 reported a mean rate of cure of 42% for PTRA, and a review by Schneider et al ( series, 759 patients undergoing surgery) 13 reported a mean rate of cure of 54% for surgery. Our current systematic review suggests a less favorable benefit:risk ratio for revascularization in patients with RAS attributed to FMD than previous nonsystematic reviews. The limited benefit of revascularization in relatively young subjects with normal renal function in virtually all cases has several plausible explanations. First, screening for FMD has considerably improved in the last decade because of the widespread use of computed tomography or magnetic resonance angiography when screening for secondary hypertension. The string-of-beads appearance, which can be detected noninvasively by these techniques, is a specific indicator of FMD. 14 However, the quantification of FMD lesions using
7 Trinquart et al Revascularization of FMD Renal Artery Stenosis 531 noninvasive techniques is difficult. 15 By contrast, the prevalence of FMD lesions in normotensive subjects, such as potential kidney donors, is relatively high It may be high as well in patients with essential hypertension. Consequently, patients with renal FMD lesions and essential hypertension may be advised to undergo PTRA, resulting in a disappointing BP outcome. This is a plausible explanation for the negative trend in the cure rate and the date of publication. Second, renal revascularization may be incomplete because of restenosis. A substantial proportion of patients received a repeat PTRA in the present series. The incidence of restenosis was also analyzed in cohort studies specifically designed to assess renal artery patency after PTRA in FMD. One study reported that restenosis levels were 6% at 12 months in 7 (25%) of 27 patients, and another study reported that 4 (11%) of 34 patients had displayed restenosis after a 3- to 25-month follow-up that was 1 grade or higher than at the end of the procedure. 21 Third, hypertension persistence could be explained by bilateral FMD lesions or the presence of a systemic disease. Nearly 25% of the patients analyzed in the present series had bilateral disease, and subgroup analysis showed a trend toward a reduced cure rate in the bilateral group. FMD is a heterogeneous disease, and its classification into subtypes is based on pathological or angiographic examination Because most patients currently undergo PTRA rather than surgery, pathological specimens are rarely available. The angiographic classification distinguishes the multifocal string-of-beads subtype (mostly medial) from unifocal or tubular subtypes (mostly nonmedial). This classification was reported in only 7 of 47 series relating to PTRA and in only 3 of 23 series relating to surgery. When specified, 7% of patients treated using PTRA or surgery had medial FMD disease. BP outcome was less favorable in patients with medial-type FMD than in those with unifocal or tubular FMD. Patient age and bilateral disease are confounding variables, because mean age is much lower and bilateral disease is less frequent in nonmedial than in medial FMD. 25 In series concerning children, the BP outcome tended to be good cure rates of 67% to % after PTRA and 6% to 88% after surgery, although the evidence is based on small numbers of patients. Our systematic review has strengths and limitations. We used a rigorous, replicable, and transparent method and identified a significantly greater number of patient series than previous reviews. 4,12,13 No languages were restricted, and we searched through gray literature. Using funnel plots, we found no evidence for publication bias (please see Figure S12). There are several limitations within any meta-analysis. Combined estimates should be interpreted cautiously because of the considerable heterogeneity across studies. Multiple definitions of hypertension cure were used, times from revascularization to follow-up varied within and across studies, and there was diversity in patient case mix, reflecting possible differences in selection criteria. Surgical series involved multiple techniques, including nephrectomy. We incorporated heterogeneity into the random effects models, and the 95% CI describes the uncertainty in the mean probability of hypertension cure. We performed sensitivity analyses. For PTRA, it revealed that small studies tended to overestimate the cure rate. Therefore, more confidence can be drawn from estimates issued from studies with patients. For surgery, similar estimates were obtained when the metaanalysis was restricted to studies including more than the median number of patients and to studies excluding patients with nephrectomy as the primary treatment. The analysis of sources of heterogeneity (subgroup and meta-regression analyses) may experience confounding variables, which is a significant problem in meta-analysis of observational studies, because these analyses are univariate. Finally, data on complications may have experienced selective reporting, and we cannot exclude publication bias, which could result in overestimating the hypertension cure rate. Nevertheless, the identified factors associated with hypertension cure are plausible: increasing age and duration of hypertension are associated with an increasing chance of renal parenchymal disease, concurrent atherosclerotic lesions or alteration in aortic compliance, and a lower chance of cure. The trend toward a decreasing probability of cure after revascularization by PTRA or surgery over time can be explained by easier screening for FMD, leading to identification of less severe forms of the disease and to widening of the indications for revascularization. Perspectives Further prospective studies are required. Well-designed cohort studies should address the identification of prognostic factors for hypertension cure, such as FMD type or bilateral disease. Standardizing the definition of BP cure (using the recognized criteria of BP inferior to 14/9 mm Hg without treatment) and using outcome assessment at a fixed follow-up for all patients are mandatory. Considering that only 1 patient in 3 has normal BP after PTRA with a 12% risk of complication, a randomized trial comparing PTRA with medical treatment for FMD should be considered. Acknowledgments We thank Sophie Guiquerro for literature search support. None. Disclosures References 1. Slovut DP, Olin JW. Fibromuscular dysplasia. N Engl J Med. 4;35: Dworkin LD, Cooper CJ. Clinical practice: renal-artery stenosis. N Engl J Med. 9;361: Streeten DH, Anderson GH Jr, Wagner S. Effect of age on response of secondary hypertension to specific treatment. Am J Hypertens. 199;3: Ramsay LE, Waller PC. Blood pressure response to percutaneous transluminal angioplasty for renovascular hypertension: an overview of published series. BMJ. 199;3: Uzzo RG, Novick AC, Goormastic M, Mascha E, Pohl M. Medical versus surgical management of atherosclerotic renal artery stenosis. Transplant Proc. 2;34: Ives NJ, Wheatley K, Stowe RL, Krijnen P, Plouin PF, van Jaarsveld BC, Gray R. Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. Nephrol Dial Transplant. 3;18: Nordmann AJ, Logan AG. Balloon angioplasty versus medical therapy for hypertensive patients with renal artery obstruction. Cochrane Database Syst Rev. 3;(3):CD2944.
8 532 Hypertension September 8. Balk E, Raman G, Chung M, Ip S, Tatsioni A, Alonso A, Chew P, Gilbert SJ, Lau J. Effectiveness of management strategies for renal artery stenosis: a systematic review. Ann Intern Med. 6;145: Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson A, Scoble J. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 9;361: Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, Rosenfield K, White C, Bettmann M, Cortell S, Puschett J, Clair DG, Cole P. Guidelines for the reporting of renal artery revascularization in clinical trials. J Vasc Interv Radiol. 3;14:S477 S Leoni CJ, Potter JE, Rosen MP, Brophy DP, Lang EV. Classifying complications of interventional procedures: a survey of practicing radiologists. J Vasc Interv Radiol. 1;12: Matsumoto AH, Spinosa DJ, Angle F, Hagspiel KD, Leung DA. Evaluation and endovascular therapy for renal artery stenosis. In: Baum S, Pentecost MJ, eds. Abram s Angiography: Interventional Radiology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 6: Schneider DB, Stanley JC, Messina MM. Renal artery fibrodysplasia and renovascular hypertension. In: Rutherford RB, ed. Vascular Surgery. 5th ed. Philadelphia, PA: W.B. Saunders; : Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, Maki JH, Leiner T, Beek FJ, Korst MB, Flobbe K, de Haan MW, van Zwam WH, Postma CT, Hunink MG, de Leeuw PW, van Engelshoven JM. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Intern Med. 4;141: ; discussion Willoteaux S, Faivre-Pierret M, Moranne O, Lions C, Bruzzi J, Finot M, Gaxotte V, Mounier-Vehier C, Beregi JP. Fibromuscular dysplasia of the main renal arteries: comparison of contrast-enhanced MR angiography with digital subtraction angiography. Radiology. 6;241: Spring DB, Salvatierra O Jr, Palubinskas AJ, Amend WJ Jr, Vincenti FG, Feduska NJ. Results and significance of angiography in potential kidney donors. Radiology. 1979;133: Cragg AH, Smith TP, Thompson BH, Maroney TP, Stanson AW, Shaw GT, Hunter DW, Cochran ST. Incidental fibromuscular dysplasia in potential renal donors: long-term clinical follow-up. Radiology. 1989; 172: Neymark E, LaBerge JM, Hirose R, Melzer JS, Kerlan RK Jr, Wilson MW, Gordon RL. Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery. Radiology. ;214: Andreoni KA, Weeks SM, Gerber DA, Fair JH, Mauro MA, McCoy L, Scott L, Johnson MW. Incidence of donor renal fibromuscular dysplasia: does it justify routine angiography? Transplantation. 2;73: Birrer M, Do DD, Mahler F, Triller J, Baumgartner I. Treatment of renal artery fibromuscular dysplasia with balloon angioplasty: a prospective follow-up study. Eur J Vasc Endovasc Surg. 2;23: Plouin PF, Darne B, Chatellier G, Pannier I, Battaglia C, Raynaud A, Azizi M. Restenosis after a first percutaneous transluminal renal angioplasty. Hypertension. 1993;21: Harrison EG Jr, McCormack LJ. Pathologic classification of renal arterial disease in renovascular hypertension. Mayo Clin Proc. 1971;46: Kincaid OW, Davis GD, Hallermann FJ, Hunt JC. Fibromuscular dysplasia of the renal arteries: arteriographic features, classification, and observations on natural history of the disease. Am J Roentgenol Radium Ther Nucl Med. 1968;4: McCormack LJ, Poutasse EF, Meaney TF, Noto TJ Jr, Dustan HP. A pathologic-arteriographic correlation of renal arterial disease. Am Heart J. 1966;72: Pannier-Moreau I, Grimbert P, Fiquet-Kempf B, Vuagnat A, Jeunemaitre X, Corvol P, Plouin PF. Possible familial origin of multifocal renal artery fibromuscular dysplasia. J Hypertens. 1997;15:
The European Consensus on Fibromuscular Dysplasia
The European Consensus on Fibromuscular Dysplasia Alexandre Persu, M.D.-PhD Cardiology Department Cliniques Universitaires Saint-Luc Catholic University of Louvain Brussels, Belgium Eur J Clin Invest.
More informationPierre Barrier Auriol Julien Canevet Guillaume Otal Philippe Rousseau Hervé Joffre Francis. Introduction
Cardiovasc Intervent Radiol (2010) 33:270 277 DOI 10.1007/s00270-010-9818-x CLINICAL INVESTIGATION Technical and Clinical Results After Percutaneous Angioplasty in Nonmedial Fibromuscular Dysplasia: Outcome
More informationFibromuscular Dysplasia (FMD) of the renal arteries Angiographic features and therapeutic options
Fibromuscular Dysplasia (FMD) of the renal arteries Angiographic features and therapeutic options Poster No.: C-0630 Congress: ECR 2012 Type: Educational Exhibit Authors: K. I. Ringe, B. Meyer, F. Wacker,
More informationEffective Health Care
Number 5 Effective Health Care Comparative Effectiveness of Management Strategies for Renal Artery Stenosis Executive Summary Background Renal artery stenosis (RAS) is defined as the narrowing of the lumen
More informationav ailab le at jou rn al h om epa g e:
Journal of Cardiology Cases (2011) 4, e163 e167 av ailab le at www.sciencedirect.com jou rn al h om epa g e: www.elsevier.com/locate/jccase Case Report In vivo intravascular ultrasound imaging of fibromuscular
More informationRENAL ARTERY PTA. JH PEREGRIN IKEM, Prague
RENAL ARTERY PTA JH PEREGRIN IKEM, Prague PTRA/Stenting PTRA technical success rate > 90 % In some patients helps control hypertension In some patients can improve kidney function Serious complications
More informationMinimally Invasive Treatment Options for Renal Artery FMD
Minimally Invasive Treatment Options for Renal Artery FMD FMDSA Meeting 2016 Alan H. Matsumoto, M.D., FSIR, FACR, FAHA Professor and Chair Department of Radiology & Medical Imaging University of Virginia
More informationOutcome and cost comparison of percutaneous transluminal renal angioplasty, renal arterial stent placement, and renal arterial bypass grafting
Outcome and cost comparison of percutaneous transluminal renal angioplasty, renal arterial stent placement, and renal arterial bypass grafting Xue F Y, Bettmann M A, Langdon D R, Wivell W A Record Status
More informationEndovascular treatment
210..217 NEPHROLOGY 2010; 15, S210 S217 doi:10.1111/j.1440-1797.2009.01243.x Endovascular treatment Date written: February 2009nep_1243 Final submission: August 2009 Authors: Robert MacGinley, Subramanian
More informationRenal artery stenosis
Renal artery stenosis Dr. Alexander Woywodt Consultant Renal Physician, Royal Preston Hospital Preston, 31.10.2007 Menu anatomy of the renal arteries diseases of the large renal arteries atherosclerotic
More informationCurrent Role of Renal Artery Stenting in Patients with Renal Artery Stenosis
Current Role of Renal Artery Stenting in Patients with Renal Artery Stenosis Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea Etiology Fibromuscular
More informationSurgical revascularization of renal artery after complicated or failed percutaneous transluminal renal angioplasty
Surgical revascularization of renal artery after complicated or failed percutaneous transluminal renal angioplasty Michel Lacombe, MD, a and Jean-Baptiste Ricco, MD, PhD, b Clichy and Poitiers, France
More informationA Closer Look: Renal Artery Stenosis. Renal artery stenosis (RAS) is defined as a TOPICS FROM CHEP. Shawn s stenosis
TOPICS FROM CHEP A Closer Look: Renal Artery Stenosis On behalf of the Canadian Hypertension Education Program (CHEP), Dr. Tobe gives an overview of renal artery stenosis, including the prevalence, screening
More informationORIGINAL ARTICLE. Department of Nephrology, Endocrinology and Metabolic Diseases, Silesian Medical University, Katowice, Poland
ORIGINAL ARTICLE Cardiology Journal 2009, Vol. 16, No. 6, pp. 514 520 Copyright 2009 Via Medica ISSN 1897 5593 Comparison of early and late efficacy of percutaneous transluminal renal angioplasty with
More informationPercutaneous Transluminal Angioplasty of Renal Artery Fibromuscular Dysplasia: Mid-term Results
Percutaneous Transluminal ngioplasty of Renal rtery Fibromuscular Dysplasia: Mid-term Results Hyo Jin Kim, MD 1 Young Soo Do, MD 1 Sung Wook Shin, MD 1 Kwang o Park, MD 1 Sung Ki ho, MD 1 Yeon Hyeon hoe,
More informationRenal Artery Stenosis: Insights from the CORAL Trial
Renal Artery Stenosis: Insights from the CORAL Trial Christopher J. Cooper, M.D., FACC, FACP Dean and Senior Vice President University of Toledo, College of Medicine President, Ohio Chapter ACC State of
More informationPCI for Renal Artery stenosis
PCI for Renal Artery stenosis Why should we treat Renal Artery Stenosis? Natural History of RAS RAS is progressive disease Study Follow-up (months) Pts Progression N (%) Total occlusion Wollenweber Meaney
More informationRenal Artery Stenting
Renal Artery Stenting J.P. Reilly, MD, FSCAI Ochsner Medical Center Speaker s bureau: Astra Zeneca and Lilly/Diachi Sankyo Prevalence of RAS is high in cath population. Renal artery intervention can help
More informationJanuary 23, Vascular and oncological interventional radiology Paris Descartes University
January 23, 2019 First time data release: Paclitaxel-coated balloon in below-the-knee lesions: 6-months results from the Ranger BTK single center study Dr. Costantino Del Giudice Prof Marc Sapoval Vascular
More informationFibromuscular dysplasia a rare cause of renovascular hypertension Case study and overview of the literature data
, pp.316 320 Fibromuscular dysplasia a rare cause of renovascular hypertension Case study and overview of the literature data Geavlete O*, Călin C*, Croitoru M*, Lupescu I**, Ginghină C* *Cardiology Department,
More informationDisclosure of Potential Conflicts. Renal Artery Stenosis. RAS Epidemiology. Road Map. Background. ASDIN 7th Annual Scientific Meeting
Renal Artery Stenosis Disclosure of Potential Conflicts Cytopherx, Inc. R4 Vascular, Inc. Bard Peripheral Vascular Spectranetics, Inc. Alexander S. Yevzlin, MD Associate Professor of Medicine (CHS) ASDIN
More informationRecommendations for Follow-up After Vascular Surgery Arterial Procedures SVS Practice Guidelines
Recommendations for Follow-up After Vascular Surgery Arterial Procedures 2018 SVS Practice Guidelines vsweb.org/svsguidelines About the guidelines Published in the July 2018 issue of Journal of Vascular
More informationRAS Epidemiology. Renal Artery Stenosis. Pathophysiology of RAS. Disclosure of Potential Conflicts. Background Pathophysiology of RAS.
Renal Artery Stenosis RAS Epidemiology Common Disease Incidence General Population 0.1% Hypertensive Population 4% HTN & Suspected CAD 10-20% Malignant HTN 20-30% Malignant HTN and CKD 30-40% Alexander
More informationRenovascular hypertension in children and adolescents
Renovascular hypertension in children and adolescents M I E C Z Y S L AW L I T W I N D E P T. O F N E P H R O LO G Y & A R T E R I A L H Y P E R T E N S I O N T H E C H I L D R E N S M E M O R I A L H
More informationNatural history and progression of atherosclerotic renal vascular stenosis
204..209 NEPHROLOGY 2010; 15, S204 S209 doi:10.1111/j.1440-1797.2009.01242.x Natural history and progression of atherosclerotic renal vascular stenosis Date written: December 2008nep_1242 Final submission:
More informationIntimal Fibromuscular Dysplasia of Renal Artery: A Rare Case of Hypertension
Case Report Intimal Fibromuscular Dysplasia of Renal 10.5005/jp-journals-10043-0010 Artery: A Rare Case of Hypertension Intimal Fibromuscular Dysplasia of Renal Artery: A Rare Case of Hypertension 1 Amit
More informationUse of polytetrafluoroethylene renal bypass
Use of polytetrafluoroethylene renal bypass grafts for P. Lagneau, M.D., J. B. Michel, M.D., and J. M. Charrat, M.D., Paris, France Fifty-six revascularizations of the renal arteries were performed in
More informationOverview of Subclavian & Innominate Artery Interventions
TCT 2016 Washington, DC, USA Tuesday November 1st, 2016 Peripheral vascular interventions Overview of Subclavian & Innominate Artery Interventions Dr Jacques Busquet Vascular & Endovascular Surgery Paris,
More informationLife After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention
Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention No Relationships to Disclose The Need for Modern Renal Trials Increased rate of RAS diagnosis
More informationUS of Renovascular Hypertension. Jonathan R. Dillman, MD, MSc Associate Professor Director, Thoracoabdominal Imaging
US of Renovascular Hypertension Jonathan R. Dillman, MD, MSc Associate Professor Director, Thoracoabdominal Imaging Disclosures Nothing Relevant Unrelated grant funding Siemens US Toshiba US Objectives
More informationRenal Fibromuscular Dysplasia: A Not So Common Entity of Secondary Hypertension
REVIEW PAPER Renal Fibromuscular Dysplasia: A Not So Common Entity of Secondary Hypertension Elias A. Sanidas, MD, PhD; 1 Maria Seferou, MD; 1 Dimitris P. Papadopoulos, MD, FESC; 1 Anastasios Makris, MD;
More information11 TH ANNUAL VASCULAR NONINVASIVE TESTING SYMPOSIUM NOVEMBER 10, 2018
11 TH ANNUAL VASCULAR NONINVASIVE TESTING SYMPOSIUM NOVEMBER 10, 2018 RENAL ARTERY DISEASE AND RENOVASCULAR HYPERTENSION 1 WHAT IS RENOVASCULAR HYPERTENSION? https://my.clevelandclinic.org/health/diseases/16459-renovascular-hypertension
More informationAtherosclerotic Renovascular Hypertension : Lessons from Recent Clinical Studies
Review ISSN 1738-5997 (Print) ISSN 2092-9935 (Online) Electrolyte Blood Press 8:87-91, 2010 doi: 10.5049/EBP.2010.8.2.87 Atherosclerotic Renovascular Hypertension : Lessons from Recent Clinical Studies
More informationRenal Artery FFR. Woo-Young Chung. Seoul National University, College of Medicine Boramae Medical Center Cardiovascular Center
Renal Artery FFR Woo-Young Chung Seoul National University, College of Medicine Boramae Medical Center Cardiovascular Center Why renal FFR? Renal artery angioplasty (PTRA) Indication of Renal artery angioplasty
More informationIs Renal Artery Stenting Still Relevant? A Cohort Analysis
Is Renal Artery Stenting Still Relevant? A Cohort Analysis Sunil Naik, MD*, Brijesh Patel, DO, Anas Souqiyyeh, MD, Marc Zughaib, David Eastes, MPH, Marcel Zughaib, MD Abstract Atherosclerotic renal artery
More informationPre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease
Pre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease Michael R. Jaff, D.O., F.A.C.P., F.A.C.C. Assistant Professor of Medicine Harvard Medical School Director, Vascular Medicine
More informationSubclavian artery Stenting
Subclavian artery Stenting Etiology Atherosclerosis Takayasu s arteritis Fibromuscular dysplasia Giant Cell Arteritis Radiation-induced Vascular Injury Thoracic Outlet Syndrome Neurofibromatosis Incidence
More informationAngioplasty with stent in renal artery stenosis: our experience
Rev Chil Radiol 2016; 22(1): 13-19. Angioplasty with stent in renal artery stenosis: our experience Johanna Marcela Vasquez Veloza *, José Luis Abades Vázquez, José Luis Cordero Castro. Interventional
More informationCase 8038 Renal allograft complicated with renal artery stenosis
Case 8038 Renal allograft complicated with renal artery stenosis Santiago I, Canelas A, Pinto AP Section: Cardiovascular Published: 2009, Nov. 30 Patient: 61 year(s), male Clinical History A 61-year-old
More informationTreatment of hypertension in patients with renal artery stenosis due to fibromuscular dysplasia of the renal arteries
Mini-Review Treatment of hypertension in patients with renal artery stenosis due to fibromuscular dysplasia of the renal arteries Steven G. Chrysant 1, George S. Chrysant 2 1 University of Oklahoma College
More informationRenal Artery Stenting With Embolic Protection
Renal Artery Stenting With Embolic Protection Embolic protection during renal stenting may be beneficial, but new device designs are necessary. BY RAJESH M. DAVE, MD Renal artery stenosis (RAS) is the
More informationAtherosclerotic renal artery stenosis and reconstruction
http://www.kidney-international.org & 2006 International Society of Nephrology mini review Atherosclerotic renal artery stenosis and reconstruction B Krumme 1 and J Donauer 2 1 Deutsche Klinik für Diagnostik,
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationRAPID Phase III Perspectives from the Medical Device Industry
RAPID Phase III Perspectives from the Medical Device Industry Megan M. Brandt Vice President, Quality and Regulatory Affairs Cardiovascular Systems, Inc. St. Paul, MN PAD and Critical Limb Ischemia: Disease
More informationSetting The setting was a hospital. The economic study was carried out in the USA.
Percutaneous stenting of incidental unilateral renal artery stenosis: decision analysis of costs and benefits Axelrod D A, Fendrick A M, Carlos R C, Lederman R J, Froehlich J B, Weder A B, Abrahamse P
More informationRenal Artery Stenosis With Severe Hypertension: A Case Report
CASE REPORT Renal Artery Stenosis With Severe Hypertension: A Case Report Suwaid MA ABSTRACT Background: Renal artery stenosis (RAS) is found in 77% of hypertensive patients and is responsible for 1-2%
More informationComparative Effectiveness Review (Update) Comparative Effectiveness of Management Strategies for Renal Artery Stenosis: 2007 Update
This report is based on research conducted by the Tufts-New England Medical Center Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville,
More informationFailed percutaneous transluminal renal angioplasty: Experience with lesions requiring operative intervention
Failed percutaneous transluminal renal angioplasty: Experience with lesions requiring operative intervention Richard H. Dean, M.D., James T. Callis, M.D., Bruce M. Smith, M.D., and Patrick W. Meacham,
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More informationCase yr old lady; type 2 Diabetes 10 yrs; PVD; hypertension
Does this patient have flash pulmonary oedema? Philip A Kalra Professor of Nephrology, Salford Royal Hospital and University of Manchester, UK 73 yr old lady; type 2 Diabetes 1 yrs; PVD; hypertension Acute
More informationFibromuscular dysplasia (FMD) is a nonatherosclerotic
Treatment of Renal Artery Fibromuscular Dysplasia Michael A. Meuse, MD, Ulku C. Turba, MD, Saher S. Sabri, MD, Auh-Whan Park, MD, Wael E. A. Saad, MD, J. Fritz Angle, MD, and Alan H. Matsumoto, MD Fibromuscular
More informationperipheral arterial disease; PAD endovascular therapy; EVT
15 603 610 2006 1 1 1 1 1 2 3 1 2 peripheral arterial disease; PAD endovascular therapy; EVT chronic total occlusion; CTO CTO TASC-C DEVT 1997 7 2006 4 PAD 171 218 EVTCTO60 61 51 9 70 8.6cm 8049 1 9 2
More informationCORAL Trial Aftermath: What Do We Do Now? Renal Revascularization in Perspective
CORAL Trial Aftermath: What Do We Do Now? Renal Revascularization in Perspective Michael R. Jaff, DO Massachusetts General Hospital Boston, Massachusetts, USA Michael R. Jaff, DO Conflicts of Interest
More informationRadiologic Evaluation of Peripheral Arterial Disease
January 2003 Radiologic Evaluation of Peripheral Arterial Disease Grace Tye, Harvard Medical School Year III Patient D.M. CC: 44 y/o male with pain in his buttocks Occurs after walking 2 blocks. Pain is
More informationAn Overview of Post-EVAR Endoleaks: Imaging Findings and Management. Ravi Shergill BSc Sean A. Kennedy MD Mark O. Baerlocher MD FRCPC
An Overview of Post-EVAR Endoleaks: Imaging Findings and Management Ravi Shergill BSc Sean A. Kennedy MD Mark O. Baerlocher MD FRCPC Disclosure Slide Mark O. Baerlocher: Current: Consultant for Boston
More informationIsolated spontaneous dissection of the renal artery
Isolated spontaneous dissection of the renal artery M. Lacombe, MD, Clichy, France Purpose: The aim of this study was to assess the results of surgical treatment in a series of patients who underwent operation
More informationType of intervention Diagnosis. Economic study type Cost-effectiveness analysis.
The utility and potential cost-effectiveness of stress myocardial perfusion thallium SPECT imaging in hospitalized patients with chest pain and normal or non-diagnostic electrocardiogram Ben-Gal T, Zafrir
More informationSetting The setting was secondary care. The economic study was conducted in Germany.
Cost-effectiveness analysis of treatment of renal-artery stenoses by medication, angioplasty, stenting and surgery Duda S H, Banz K, Brehme U, Erley CM, Albes J, Tepe G, Wiskirchen J, Claussen C D Record
More informationCoral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.
Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.. Dr. Javier Ruiz Aburto, FACS, FICS Assistant Professor Ponce School of Medicine Puerto Rico
More informationMichael Meuse, M.D. Vascular and Interventional Radiology
Michael Meuse, M.D. Vascular and Interventional Radiology Which patient would likely benefit from renal artery revascularization? Patient A- 60 y/o male with 20 year hx of htn; on 2 drug therapy for 10
More informationRevascularization versus Medical Therapy for Renal-Artery Stenosis
The new england journal of medicine original article versus Medical Therapy for Renal-Artery Stenosis The ASTRAL Investigators* Abstract Background Percutaneous revascularization of the renal arteries
More informationThe role of renal autotransplantation in pediatric and young adult patients with renal artery disease
The role of renal autotransplantation in pediatric and young adult patients with renal artery disease Mark L. Jordan, M.D., Andrew C. Novick, M.D., and Robert L. Ctmningham, M.D., Cleveland, Ohio From
More informationShould percutaneous transluminal renal angioplasty be applied to ostial renal artery atherosclerosis?
Should percutaneous transluminal renal angioplasty be applied to ostial renal artery atherosclerosis? artery Jens Eldrup-Jorgensen, MD, H. Russell Harvey, MD, Lawrence N. Sampson, MD,* Steven M. Amberson,
More informationEuropean consensus on the diagnosis and management of fibromuscular dysplasia
Consensus Document European consensus on the diagnosis and management of fibromuscular dysplasia Alexandre Persu a,b, Alessandra Giavarini c,d, Emmanuel Touzé e, Andrzej Januszewicz f, Marc Sapoval g,h,
More informationRenal artery stenosis treated with stent deployment: Indications, technique, and outcome for 108 patients
Renal artery stenosis treated with stent deployment: Indications, technique, and outcome for 108 patients Julio A. Rodriguez-Lopez, MD, Alan Werner, MD, Lance I. Ray, MD, Christos Verikokos, MD, Luis J.
More informationDuplex Ultrasound of the Renal Arteries. Duplex Ultrasound. In the Beginning
Duplex Ultrasound of the Renal Arteries DIMENSIONS IN HEART AND VASCULAR CARE 2013 PENN STATE HEART AND VASCULAR INSTITUTE ROBERT G. ATNIP MD PROFESSOR OF SURGERY AND RADIOLOGY Duplex Ultrasound Developed
More informationSuccessful Ex-Vivo Repair of an Intrahilar Renal Artery Aneurysm with Autotransplantation
ISPUB.COM The Internet Journal of Surgery Volume 20 Number 2 Successful Ex-Vivo Repair of an Intrahilar Renal Artery Aneurysm with Autotransplantation P Andrejevic, R Giordmaina, J Psaila, A Attard Citation
More informationCase report. Open Access. Abstract
Open Access Case report Renal artery rupture following cutting balloon angioplasty for fibromuscular dysplasia: a case report Elias N Brountzos 1 *, Nikolaos Ptohis 1, Helen Triantafyllidi 2, Irene Panagiotou
More informationCT Versus MR for the Runoff
CT Versus MR for the Runoff Robert R. Edelman, M.D. Dept. of Radiology NorthShore University HealthSystem Feinberg School of Medicine, Northwestern University Magnetic Resonance Computed Tomography Radio
More informationThe role of percutaneous revascularization for renal artery stenosis
The role of percutaneous revascularization for renal artery stenosis Gregory J Dubel and Timothy P Murphy Abstract: Renal artery stenosis (RAS) is usually caused by atherosclerosis or fibromuscular dysplasia.
More informationCurrent Health Sciences Journal Vol. 36, No. 4, Renal Artery Stenosis Due To Ischemic Nephropathy ALINA-GABRIELA PĂUNA
Original Paper Renal Artery Stenosis Due To Ischemic Nephropathy ALINA-GABRIELA PĂUNA Department of Nephrology, St. John Emergency Hospital, Bucharest ABSTRACT This paper approach a relatively old problem:
More informationFMD 101. Esther S.H. Kim, MD, MPH, FACC, FSVM FMDSA Annual Meeting 18 May 2013
FMD 101 Esther S.H. Kim, MD, MPH, FACC, FSVM FMDSA Annual Meeting 18 May 2013 Back to basics Blood Bodily fluid that transports necessary substances (oxygen, nutrients, antibodies, hormones, etc) and waste
More informationEndovascular treatment of thrombosis (acute) of aneurysm through bifurcated endoprothesis: challenge cases
Endovascular treatment of thrombosis (acute) of aneurysm through bifurcated endoprothesis: challenge cases Fábio Luiz Costa Pereira Fabrício Machado Rossi Pablo da Silva Mendes Carlos Andre Daher Victor
More informationRENAL AND MESENTERIC ARTERY STENTS Are There Standard Velocity Criteria for Restenosis?
RENAL AND MESENTERIC ARTERY STENTS Are There Standard Velocity Criteria for Restenosis? R. Eugene Zierler, M.D. The D. E. Strandness, Jr. Vascular Laboratory University of Washington Medical Center Division
More informationMultislice CTA for Renal Artery Stenting
Multislice CT for Renal rtery Stenting How CT can be a useful modality for diagnosing and managing renal artery stenosis for stent placement. Y MICHEL WHOLEY, MD, M; JMES WU, ; WILLIM C.L. WU, MD, FCC;
More informationLessons & Perspectives: What is the role of Cryoplasty in SFA Intervention?
Lessons & Perspectives: What is the role of Cryoplasty in SFA Intervention? Michael Wholey, MD, MBA San Antonio, TX USA 19/06/2009 at 09:35 during 4mn as a Speaker Session: Improving Femoral Artery Recanalization
More informationStatins in the elderly: What evidence of their benefit in prevention?
Archives of Cardiovascular Disease (2010) 103, 61 65 SCIENTIFIC EDITORIAL Statins in the elderly: What evidence of their benefit in prevention? Les statines chez les personnes âgées : quelle preuve de
More information4/29/2012. Management of Central Vein Stenoses. Central Venous Stenoses and Occlusions
Central Venous Stenoses and Occlusions Management of Central Vein Stenoses Robert K. Kerlan Jr. M.D. Professor of Clinical Radiology and Surgery University of California San Francisco Key Questions What
More informationA Unique Case of Renovascular Hypertension due to Fibromuscular Dysplasia in an Extra-renal Artery
doi: 10.2169/internalmedicine.0023-17 Intern Med 57: 2689-2694, 2018 http://internmed.jp CASE REPORT A Unique Case of Renovascular Hypertension due to Fibromuscular Dysplasia in an Extra-renal Artery Ikki
More informationPeripheral Vascular Disease
Peripheral artery disease (PAD) results from the buildup of plaque (atherosclerosis) in the arteries of the legs. For people with PAD, symptoms may be mild, requiring no treatment except modification of
More informationVisceral aneurysm. Diagnosis and Interventions M.NEDEVSKA
Visceral aneurysm Diagnosis and Interventions M.NEDEVSKA History 1953 De Bakeyand Cooley Visceral aneurysm VAAs rare, reported incidence of 0.01 to 0.2% on routine autopsies. Clinically important Potentially
More informationAccessory Renal Arteries: A Cadaveric Study
Accessory Renal Arteries: A Cadaveric Study Bina.K.Katariya 1*, Priyank Bhabhor 2, H.R.Shah 3. 1, 2 Third year resident, 3 Additional Professor, Department of anatomy, B.J.Medical College, Ahmedabad, Gujarat
More informationSalvageability of renal function following renal revascularization in children with Takayasu arteritis-induced renal artery stenosis
Salvageability of renal function following renal revascularization in children with Takayasu arteritis-induced renal artery stenosis Obiagwu P 1, Gajjar P 1, Scott C 1, Numanoglu A 2, McCulloch M, 1 Nourse
More informationBEST OF Groupe Vasculaire Thrombose
BEST OF Groupe Vasculaire Thrombose Serge Kownator (Thionville) Claire Mounier Vehier (Lille) Gérard Helft (Paris) Victor ABOYANS (Limoges) Boris ALEIL (Strasbourg) Serge COHEN (Marseille) Joseph EMMERICH
More informationNOT FOR PUBLICATION, QUOTATION, OR CITATION RESOLUTION NO. 22
BE IT RESOLVED, Sponsored By: RESOLUTION NO. 22 that the American College of Radiology adopt the ACR SIR Practice Parameter for the Performance of Angiography, Angioplasty, and Stenting for the Diagnosis
More informationRenal artery stenting- A pictorial review of stent designs, indications and outcomes
Renal artery stenting- A pictorial review of stent designs, indications and outcomes Poster No.: C-1644 Congress: ECR 2012 Type: Educational Exhibit Authors: C. Tingerides, S. McPherson, S. Puppala ; Leeds/UK,
More informationafter treatment of Renal duplex sonography renovascular disease
Renal duplex sonography renovascular disease after treatment of Dudley A. Hudspeth, MD, Kimberley J. Hansen, MD, Scott W. Reavis, RVT, Susan M. Start, RN, Richard G. Appel, MD, and Richard H. Dean, MD,
More informationHandbook Of Angioplasty And Stenting
Handbook Of Angioplasty And Stenting Procedures (techniques In Interventional Radiology) The 1 handbook in interventional radiology covers all current procedures from Free ebook: Handbook of Angioplasty
More informationEndovascular Management of Thoracic Aortic Pathology Stéphan Haulon, J Sobocinski, B Maurel, T Martin-Gonzalez, R Spear, A Hertault, R Azzaoui
Endovascular Management of Thoracic Aortic Pathology Stéphan Haulon, J Sobocinski, B Maurel, T Martin-Gonzalez, R Spear, A Hertault, R Azzaoui Aortic Center, Lille University Hospital, France Disclosures
More informationVascular Imaging Original Research
MDCT Angiography of Renal Arteries Vascular Imaging Original Research Adam D. Talenfeld 1 Ryan B. Schwope Huntley J. Alper Emil I. Cohen Robert A. Lookstein Talenfeld AD, Schwope RB, Alper HJ, Cohen EI,
More informationMahatma Gandhi Medical College and Hospital, Mahatma Gandhi University of Health Sciences and Technology, RIICO, Sitapura, Jaipur, India
Scholars Journal of Medical Case Reports Sch J Med Case Rep 2016; 4(2):105-109 Scholars Academic and Scientific Publishers (SAS Publishers) (An International Publisher for Academic and Scientific Resources)
More informationThoracic Endovascular Aortic Repair (TEVAR) Indications and Basic Procedure
Thoracic Endovascular Aortic Repair (TEVAR) Indications and Basic Procedure Tilo Kölbel, MD, PhD University Heart Center Hamburg University Hospital Eppendorf Disclosure Speaker name: Tilo Kölbel, MD I
More informationTreatment options for endoleaks: stents, embolizations and conversions
Treatment options for endoleaks: stents, embolizations and conversions Poster No.: C-0861 Congress: ECR 2012 Type: Authors: Keywords: DOI: Scientific Exhibit G. Lombardi; napoli/it Arteries / Aorta, Abdomen,
More informationVARIANT ORIGIN OF RENAL ARTERIES AND ITS CLINICAL IMPLICATION
VARIANT ORIGIN OF RENAL ARTERIES AND ITS CLINICAL IMPLICATION Krunal Chauhan,*Shweta J. Patel, Rashvaita K. Patel, Mehta C.D. and Maunil Desai Department of Anatomy, Government Medical College, Surat,
More informationVasile Goldiş Western University of Arad Faculty of Medicine, Pharmacy and Dental Medicine, Arad, Romania
ENDOVASCULAR TREATMENT FOR VASCULAR GRAFT RESTENOSIS Bogdan Totolici 1, Francisca Blanca Călinescu 1*, Ionel Droc 2, Carmen Neamţu 1 1 Vasile Goldiş Western University of Arad Faculty of Medicine, Pharmacy
More informationEndovascular treatment of popliteal artery aneurysm: preliminary results
Endovascular treatment of popliteal artery aneurysm: preliminary results Poster No.: C-0483 Congress: ECR 2012 Type: Scientific Paper Authors: G. Guzzardi, R. Fossaceca, P. Cerini, C. Stanca, I. Di Gesù,
More informationAngiosome concept myth or truth? Does it make a real difference in real world cases?
Angiosome concept myth or truth? Does it make a real difference in real world cases? Osamu Iida, MD, FACC Kansai Rosai Hospital Amagasaki, Hyogo, Japan Disclosure Speaker name:... I have the following
More informationThe Centers for Medicare & Medicaid Services
Percutaneous Renal Revascularization and Medicare Coverage The Society of Interventional Radiology s position on the current CMS coverage of renal interventions. BY DAVID SACKS, MD, AND TIMOTHY P. MURPHY,
More informationDCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
More information